M.T.E.-4 1 MG
ZINC (ZINC SULFATE) : 1 MG COPPER (CUPRIC SULFATE) : 0.4 MG CHROMIUM (CHROMIC CHLORIDE) : 4 MCG MANGANESE (MANGANESE SULFATE) : 0.1 MG · DIN 02139278 · PHARMACEUTICAL PARTNERS OF CANADA INC
Health Canada status: CANCELLED POST MARKET
What is M.T.E.-4?
M.T.E.-4 1 MG contains ZINC (ZINC SULFATE) : 1 MG COPPER (CUPRIC SULFATE) : 0.4 MG CHROMIUM (CHROMIC CHLORIDE) : 4 MCG MANGANESE (MANGANESE SULFATE) : 0.1 MG. It is listed in the Health Canada Drug Product Database under DIN 02139278, held by PHARMACEUTICAL PARTNERS OF CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 15-Feb-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is M.T.E.-4 called?
The same molecule, COMBINATIONS OF ELECTROLYTES, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ekyflogyl | Latin | Iceland |
| OTIPAX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02139278 |
|---|---|
| Brand name | M.T.E.-4 |
| Generic / active ingredient | ZINC (ZINC SULFATE) : 1 MG COPPER (CUPRIC SULFATE) : 0.4 MG CHROMIUM (CHROMIC CHLORIDE) : 4 MCG MANGANESE (MANGANESE SULFATE) : 0.1 MG |
| Manufacturer | PHARMACEUTICAL PARTNERS OF CANADA INC |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA30 COMBINATIONS OF ELECTROLYTES |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Feb-2008 |
| Original market date | 1996-08-14 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02139278 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2139278 |
| Brand name | M.T.E.-4 |
| Active ingredient / INN | ZINC (ZINC SULFATE) : 1 MG COPPER (CUPRIC SULFATE) : 0.4 MG CHROMIUM (CHROMIC CHLORIDE) : 4 MCG MANGANESE (MANGANESE SULFATE) : 0.1 MG |
| ATC code | B05XA30 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05 |
| AHFS class | 40:12.00 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | PHARMACEUTICAL PARTNERS OF CANADA INC |
Which pack is which?
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code B05XA30 COMBINATIONS OF ELECTROLYTES. 1 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TPN ELECTROLYTES | 16.55 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00590215 |
| CARBICARB INJECTION | 35 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00757004 |
| HYPERLYTE (MULTI-ELECTROLYTE CONCENTRATE) | 690 MG / 25 ML | LIQUID | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | DIN 01963910 |
| LYPHOLYTE | 2.5 G / 20 ML | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | DIN 02139618 |
| LYPHOLYTE MULTI-ELECTROLYTE CONC INJ | 43 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01944940 |
| M.T.E.-4 CONCENTRATED | 10 MCG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | DIN 02139251 |
| M.T.E.-6 CONCENTRATED | 5 MG | SOLUTION | PHARMACEUTICAL PARTNERS OF CANADA INC | CANCELLED POST MARKET | DIN 02139235 |
| MTE 4 INJ | 1 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01945319 |
| MULTIPLE ELECTROLYTE ADDITIVE INJ | 29.8 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00421952 |
Who else supplies COMBINATIONS OF ELECTROLYTES worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS OF ELECTROLYTES appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does COMBINATIONS OF ELECTROLYTES cost around the world?
COMBINATIONS OF ELECTROLYTES is listed on 4 national price registers Nexara tracks, across 8 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 5 | 5 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
| Luxembourg | reimbursement | 1 | 1 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.